Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Leichte Bedienung, intuitive Suche: Die Betaversion unseres neuen Katalogs ist online! → Zur Betaversion des neuen DNB-Katalogs

24. Dezember 2025 bis 1. Januar 2026: Die Deutsche Nationalbibliothek bleibt an beiden Standorten geschlossen. Bestellte Medien werden am 2. Januar 2026 bereitgestellt. // 24 December 2025 to 1 January 2026: The German National Library will be closed at both locations. Ordered media will be made available on 2 January 2026.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

101 - 110 von 146

	101	Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study Enthalten in Drug safety Bd. 42, 21.6.2019, Nr. 12, date:12.2019: 1437-1447
	102	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) Enthalten in BioDrugs Bd. 35, 15.7.2021, Nr. 4, date:7.2021: 417-428
	103	Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim Enthalten in Annals of hematology Bd. 103, 8.1.2024, Nr. 3, date:3.2024: 947-956
	104	Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis Enthalten in Indian journal of gastroenterology Bd. 41, 15.11.2022, Nr. 5, date:10.2022: 446-455
	105	Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study Enthalten in BioDrugs Bd. 38, 22.11.2023, Nr. 1, date:1.2024: 121-131
	106	Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials Enthalten in BioDrugs Bd. 34, 23.9.2020, Nr. 5, date:10.2020: 681-694
	107	Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review Enthalten in BioDrugs Bd. 32, 22.5.2018, Nr. 3, date:6.2018: 193-199
	108	Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with rheumatoid arthritis: a 12-month observational study Enthalten in Advances in rheumatology Bd. 65, 10.10.2025, Nr. 1, date:12.2025: 1-5
	109	Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study Enthalten in BioDrugs Bd. 35, 16.10.2021, Nr. 6, date:11.2021: 735-748
	110	Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin Enthalten in Diabetes therapy Bd. 13, 1.6.2022, Nr. 7, date:7.2022: 1299-1310